Clinical trial
Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS
NCT03775746 is registered in ClinicalTrials.gov with East and North Hertfordshire NHS Trust as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS
- Lead sponsor
- East and North Hertfordshire NHS Trust
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- January 8, 2019
- Completion date
- December 31, 2021
- Enrollment
- 150 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.